Erythropoietin

Generic Name: Erythropoietin

Brand Names: Procrit, Eprex, Epprex, Epoetin Alfa Hexal, Silapo, Biopoin, Abseamed, Eporatio, NeoRecormon, Epogen, Retacrit

Drug Type: Biotech

Chemical Formula: -

CAS Number: 11096-26-7

Unique Ingredient Identifier: 64FS3BFH5W

Background: Erythropoietin (EPO) is a growth factor produced in the kidneys that stimulates the production of red blood cells. It works by promoting the division and differentiation of committed erythroid progenitors in the bone marrow . Epoetin alfa (Epoge) was developed by Amgen Inc. in 1983 as the first rhEPO commercialized in the United States, followed by other alf...

Indication: 用于肾功能不全合并的贫血，艾滋病本身或因治疗引起的贫血，恶性肿瘤伴发的贫血及风湿性贫血等。另外，为择期手术储存自体血而反复采血的患者，同时应用本品可预防发生贫血。

Associated Conditions: Anemia, Blood Loss During Surgery, Anemia caused by Zidovudine

Associated Therapies: -

Clinical Trials

Treatment of Myelodysplastic Syndrome (MDS) With Cytokine-Immunotherapy for Low-Risk MDS

Phase 2

Completed

Conditions: Myelodysplastic Syndrome

Interventions: Drug: Erythropoietin
Drug: Cyclosporin A
Drug: G-CSF
Drug: Prednisone

First Posted Date: 2007-08-24

Last Posted Date: 2012-08-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 15

Registration Number: NCT00520468

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Clinical Study of R744 to Predialysis Patients( Phase III, Comparative Study in Comparison With Epoetin Beta)

Phase 3

Completed

Conditions: Predialysis Patients

Interventions: Drug: R744
Drug: Epoetin beta

First Posted Date: 2007-06-27

Last Posted Date: 2009-01-08

Lead Sponsor: Chugai Pharmaceutical

Target Recruit Count: 187

Registration Number: NCT00492427

Locations: 🇯🇵
Kanto/Koshinetsu region, Kanto/Koshinetsu, Japan
🇯🇵
Kyusyu region, Kyusyu, Japan
🇯🇵
Kinki/Hokuriku region, Kinki/Hokuriku, Japan

and more 3 locations

Clinical Study of R744 to Hemodialysis Patients

Phase 3

Completed

Conditions: Hemodialysis Patients

Interventions: Drug: R744
Drug: rHuEPO
Drug: R744 placebo
Drug: rHuEPO placebo

First Posted Date: 2007-06-26

Last Posted Date: 2009-02-02

Lead Sponsor: Chugai Pharmaceutical

Target Recruit Count: 134

Registration Number: NCT00491868

Locations: 🇯🇵
Kyusyu region, Kyusyu, Japan
🇯🇵
Chubu region, Chubu, Japan
🇯🇵
Kanto/Koshinetsu region, Kanto/Koshinetsu, Japan

and more 2 locations

A Study Comparing Mircera and Epoetin Beta for the Treatment of Anemia in Dialysis Patients With Chronic Kidney Disease.

Phase 3

Completed

Conditions: Anemia

Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera]
Drug: Epoetin beta

First Posted Date: 2007-03-02

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 265

Registration Number: NCT00442793

Anti-Restenosis After AMI by Erythropoietin

Phase 4

Conditions: Acute Myocardial Infarction

First Posted Date: 2007-01-17

Last Posted Date: 2007-01-17

Lead Sponsor: Kyoto Prefectural University of Medicine

Target Recruit Count: 72

Registration Number: NCT00423020

Locations: 🇯🇵
Kyoto Prefectural University of Medicine, Kyoto, Japan

Erythropoietin Treatment in Patients With Systolic Left Ventricular Dysfunction, Mild Anemia and Normal Renal Function

Phase 4

Conditions: Heart Failure

First Posted Date: 2007-01-04

Last Posted Date: 2007-01-04

Lead Sponsor: Rabin Medical Center

Target Recruit Count: 10

Registration Number: NCT00418119

Locations: 🇮🇱
Cardiology Department, Rabin Medical Center, Petah Tikva, Israel

Efficacy Study of Erythropoietin After Revascularization in Myocardial Infarction (REVIVAL-3)

Phase 3

Completed

Conditions: Myocardial Infarction
Angioplasty, Transluminal, Percutaneous Coronary

Interventions: Other: Placebo
Drug: Erythropoietin

First Posted Date: 2006-10-20

Last Posted Date: 2010-12-17

Lead Sponsor: Deutsches Herzzentrum Muenchen

Target Recruit Count: 138

Registration Number: NCT00390832

Locations: 🇩🇪
Deutsches Herzzentrum Muenchen, Munich, Germany
🇩🇪
1. Medizinische Klinik, Klinikum rechts der Isar, Munich, Germany

Azacitidine and Erythropoietin Versus Azacitidine Alone for Patients With Low-Risk Myelodysplastic Syndromes

Phase 2

Terminated

Conditions: Myelodysplastic Syndromes

Interventions: Drug: Azacitidine (Monotherapy)
Drug: Azacitidine
Drug: Erythropoietin

First Posted Date: 2006-09-25

Last Posted Date: 2018-02-14

Lead Sponsor: Larry Cripe, MD

Target Recruit Count: 15

Registration Number: NCT00379912

Locations: 🇺🇸
Center for Hematology-Oncology of S Michigan, Jackson, Michigan, United States
🇺🇸
Horizon Oncology Center, Lafayette, Indiana, United States
🇺🇸
Indiana University Cancer Center, Indianapolis, Indiana, United States

and more 6 locations

Safety and Efficacy Study of Erythropoietin as add-on Therapy of Methylprednisolone to Treat Acute Optic Neuritis

Phase 2

Completed

Conditions: Optic Neuritis

Interventions: Drug: Erythropoietin

First Posted Date: 2006-07-21

Last Posted Date: 2012-09-13

Lead Sponsor: Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH

Target Recruit Count: 40

Registration Number: NCT00355095

Locations: 🇩🇪
Department of Neurology University Hospital Goettingen, Goettingen, Niedersachsen, Germany
🇩🇪
University Hospital of Hamburg-Eppendorf (Institut of Neuroimmunology and Clinical MS Research (INIMS)), Hamburg, Germany
🇩🇪
Department of Neurology University Homborg Hospital of the Saarland, Germany, Homburg, Saarland, Germany

(ACORD Study) - A Study of NeoRecormon (Epoetin Beta) in Patients With Early Diabetic Nephropathy

Phase 3

Completed

Conditions: Anemia

Interventions: Drug: Epoetin beta

First Posted Date: 2006-07-20

Last Posted Date: 2016-03-31

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 170

Registration Number: NCT00354341

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy